EUVIMEDEUVIMED entdecken
Open Access

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa

Christophe Le Terrier iD, Samanta Freire, Clément Viguier, Jacqueline Findlay iD, Patrice Nordmann iD, Laurent Poirel iD

Antimicrobial Agents and Chemotherapy · 10.05.2024

DOI: 10.1128/aac.01570-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 10.05.2024. Verfasst von Christophe Le Terrier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Escherichia coli, Microbial Sensitivity Tests, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xeruborbactam is a newly developed β-lactamase inhibitor designed for metallo-β-lactamases (MBLs). This study assessed the relative inhibitory properties of this novel inhibitor in comparison with another MBL inhibitor, namely taniborbactam (TAN), against a wide range of acquired MBL produced either in Escherichia coli or Pseudomonas aeruginosa . As observed with taniborbactam, the combination of xeruborbactam (XER) with β-lactams, namely, ceftazidime, cefepime and meropenem, led to significantly decreased MIC values for a wide range of B1-type MBL-producing E. coli , including most recombinant strains producing NDM, VIM, IMP, GIM-1, and DIM-1 enzymes. Noteworthily, while TAN-based combinations significantly reduced MIC values of β-lactams for MBL-producing P. aeruginosa recombinant strains, those with XER were much less effective. We showed that this latter feature was related to the MexAB-OprM efflux pump significantly impacting MIC values when testing XER-based combinations in P. aeruginosa . The relative inhibitory concentrations (IC 50 values) were similar for XER and TAN against NDM and VIM enzymes. Noteworthily, XER was effective against NDM-9, NDM-30, VIM-83, and most of IMP enzymes, although those latter enzymes were considered resistant to TAN. However, no significant inhibition was observed with XER against IMP-10, SPM-1, and SIM-1 as well as the representative subclass B2 and B3 enzymes, PFM-1 and AIM-1. The determination of the constant inhibition ( K i ) of XER revealed a much higher value against IMP-10 than against NDM-1, VIM-2, and IMP-1. Hence, IMP-10 that differs from IMP-1 by a single amino-acid substitution (Val67Phe) can, therefore, be considered resistant to XER.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaEscherichia coliMicrobial Sensitivity Testsbeta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsCeftazidimeMeropenemCefepimeBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

IMPNDMVIMefflux pumpmetallo-β-lactamaseporin deficiencytaniborbactamxeruborbactam

Substanzen

beta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentstaniborbactamCeftazidimeMeropenemCefepimeBorinic AcidsCarboxylic Acids

Autor:innen und Institutionen

  • Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
  • Infectious Disease Department, University hospital of Toulouse, Toulouse, France.
  • Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland.

ORCID-Profile: Christophe Le Terrier, Jacqueline Findlay, Patrice Nordmann, Laurent Poirel

Förderung

  • University of Fribourg

Zitieren

APA

Le Terrier, C., Freire, S., Viguier, C., Findlay, J., Nordmann, P., & Poirel, L. (2024). Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01570-23

Vancouver

Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01570-23

BibTeX
@article{LeTerrier2024,
  author = {Le Terrier, Christophe and Freire, Samanta and Viguier, Clément and Findlay, Jacqueline and Nordmann, Patrice and Poirel, Laurent},
  title = {Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01570-23}
}
Kostenlos starten →